Core Viewpoint - The stock price of Pulaike has shown a positive trend with a year-to-date increase of 6.44%, reflecting a strong performance in the animal health sector [2] Group 1: Stock Performance - As of January 13, Pulaike's stock price rose by 2.00% to 13.23 CNY per share, with a trading volume of 46.33 million CNY and a turnover rate of 1.02% [1] - The stock has increased by 3.93% over the last five trading days and 2.40% over the last twenty days, while it has decreased by 4.68% over the last sixty days [2] Group 2: Company Overview - Pulaike Bioengineering Co., Ltd. was established on June 22, 2002, and went public on May 18, 2015. The company is primarily engaged in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2] - The revenue composition of Pulaike includes poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2] Group 3: Financial Performance - For the period from January to September 2025, Pulaike achieved an operating income of 823 million CNY, representing a year-on-year growth of 8.04%. The net profit attributable to shareholders was 157 million CNY, reflecting a significant increase of 47.86% [2] - Since its A-share listing, Pulaike has distributed a total of 1.125 billion CNY in dividends, with 568 million CNY distributed over the past three years [3] Group 4: Shareholder Information - As of September 30, 2025, Pulaike had 16,700 shareholders, a decrease of 7.26% from the previous period, with an average of 20,739 circulating shares per shareholder, an increase of 7.83% [2] - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the sixth largest, holding 5.4716 million shares, an increase of 2.0217 million shares from the previous period [3]

Group 1 - The core viewpoint of the news is that He Yuan Bio has shown a significant increase in stock price and trading activity, indicating positive market sentiment towards the company [1] - As of January 13, He Yuan Bio's stock price rose by 2.03% to 79.57 CNY per share, with a total market capitalization of 28.446 billion CNY [1] - The company has experienced a year-to-date stock price increase of 15.14%, with a 10.09% rise over the last five trading days and a 2.62% increase over the last 20 days [1] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [1] - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, a significant increase of 84,075% compared to the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million CNY, also a decrease of 8.44% year-on-year [2]

Core Viewpoint - The stock of Chitianhua has shown fluctuations with a recent increase of 2.02%, reflecting a total market capitalization of 4.256 billion yuan, while the company faces challenges with declining revenue and net profit [1][2]. Group 1: Stock Performance - As of January 13, Chitianhua's stock price reached 2.52 yuan per share, with a trading volume of 47.56 million yuan and a turnover rate of 1.51% [1]. - Year-to-date, the stock has increased by 5.88%, with a 1.61% rise over the last five trading days, a 7.69% decline over the last 20 days, and a 6.33% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Chitianhua reported a revenue of 1.569 billion yuan, representing a year-on-year decrease of 7.96% [2]. - The company recorded a net profit attributable to shareholders of -152 million yuan, a significant decline of 340.46% compared to the previous year [2]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Chitianhua was 57,600, a decrease of 15.09% from the previous period [2]. - The average number of tradable shares per shareholder increased by 17.77% to 22,191 shares [2]. Group 4: Business Overview - Chitianhua, established on August 28, 1998, and listed on February 21, 2000, is primarily engaged in nitrogen fertilizer and methanol chemical businesses, as well as pharmaceutical distribution and manufacturing [1]. - The revenue composition of the company includes urea (55.06%), methanol (28.10%), compound fertilizer (7.61%), medical services (4.31%), and other segments [1].

近日，由福建省、厦门市、全国社会保障基金理事会、中国建设银行共同发起设立的福建（厦门）社保 科创股权投资基金合伙企业（有限合伙）顺利通过中国证券投资基金业协会备案，标志着全国社会保障 基金理事会与福建省、厦门市的战略合作正式落地。 据悉，下一步，该基金将构建"国家级资本引导、地方政府赋能、市场化机制运作"的合作模式，秉持市 场化、法治化、专业化运作原则，高效联动头部投资机构、金融机构、产业资本、科研院所等多元化社 会力量，充分链接本地优质产业、创新资源，加力培育长期资本、耐心资本助力经济结构升级，推动科 技创新和产业创新深度融合。 （厦门日报记者 陈泥） 福建（厦门）社保科创股权投资基金合伙企业（有限合伙）执行事务合伙人为厦门市创业投资有限公 司、建信金投私募基金管理（北京）有限公司，经营范围为以私募基金从事股权投资、投资管理、资产 管理等活动。 合伙人信息显示，该基金由全国社会保障基金理事会、厦门产投新兴科创合伙企业（有限合伙）、建信 金融资产投资有限公司等共同出资，首期规模200亿元，采用"上下两层、联合管理"管理架构，将紧密 围绕国家重大产业政策导向、福建省"555X"产业集群和厦门"4+4+6"现代化 ...

科创中心建设成就斐然 扩围提质势在必行 国际科技创新中心是在全球科技创新活动中占据引领和支配地位、在全球价值网络中发挥显著增值 作用的城市或地区，具有科学研究、技术创新、产业驱动和文化引领等功能，呈现科技创新资源密集、 科技创新活动活跃、科技创新能力强大、科技创新影响广泛等特征。积极谋划建设国际科技创新中心， 并发挥其在区域创新发展中的引领作用，已成为世界主要国家应对新一轮科技革命和产业变革、增强国 家综合竞争力的战略举措。 党的十八大以来，以习近平同志为核心的党中央部署北京、上海、粤港澳大湾区三大国际科技创新 中心建设，已经取得明显成效。三大中心建设启动以来，大力加强原始创新，产出一批原创性成果，集 聚形成若干先进制造业集群，辐射引领作用持续显现。在世界知识产权组织发布的2025年全球百强创新 集群排名中，我国拥有的全球百强创新集群数量连续3年位居第一，深圳—香港—广州集群跃居全球首 位。 在国际科技创新中心建设过程中，三地具有很多共性，同时又各显优势。北京集聚优质科教资源， 基础研究和原始创新能力突出，在打造世界主要科学中心和创新高地、促进重大原创性成果产出等方面 成效明显；上海坚持科技创新与体制机制创新 ...

Core Insights - The Ministry of Commerce has issued the "Comprehensive Pilot Task for Expanding Service Industry Opening in Dalian and Eight Other Cities," with Shenzhen being one of the pilot cities, receiving significant policy support to enhance its service industry opening [1][2] Group 1: Policy Support and Initiatives - Shenzhen will benefit from policies such as optimizing and upgrading the functions of free trade accounts and promoting the trial use of electronic bills of lading in shipping and trade [1] - The pilot task assigns a total of 159 tasks to nine cities, including Dalian, Ningbo, Xiamen, Qingdao, Shenzhen, Hefei, Fuzhou, Xi'an, and Suzhou, with a focus on building a socialist demonstration zone with Chinese characteristics [1] Group 2: Financial Sector Developments - The pilot task supports qualified foreign institutions to establish or invest in pension management companies in Shenzhen, which is a significant breakthrough for financial sector opening [2] - The introduction of foreign pension management companies is expected to bring long-term, stable institutional capital to Shenzhen, broadening financing channels for enterprises, particularly in the growing sectors of biomedicine and artificial intelligence [2] Group 3: Trade Efficiency Improvements - The pilot task aims to promote the trial use of electronic bills of lading in shipping and trade, addressing issues related to the slow transmission and verification of traditional paper bills [2] - The online circulation and verification of electronic bills of lading will significantly shorten the delivery and settlement cycles, enhancing the efficiency of shipping trade in Shenzhen and solidifying its position as a global shipping and logistics hub [2]

Core Viewpoint - Haoyuan Pharmaceutical's stock has shown a positive trend with an 11.90% increase year-to-date and a 7.82% increase over the last five trading days, indicating strong market performance and investor interest [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents (68.97%), with product sales contributing 63.42%, raw materials and intermediates 30.46%, technical services 5.55%, and others 0.57% [1] Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, reflecting a 65.09% increase [2] - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, while the average circulating shares per person increased by 6.77% to 17,647 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 2.3457 million shares, and new entrants such as Huatai-PineBridge Healthcare Mixed Fund and China Europe Medical Innovation Stock A [3]

责任编辑：小浪快报 我武生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：干细胞、生物医 药、创新药、人工智能、智慧医疗等。 截至9月30日，我武生物股东户数3.24万，较上期减少6.22%；人均流通股14927股，较上期增加6.63%。 2025年1月-9月，我武生物实现营业收入8.53亿元，同比增长16.86%；归母净利润3.45亿元，同比增长 26.67%。 分红方面，我武生物A股上市后累计派现9.13亿元。近三年，累计派现3.17亿元。 机构持仓方面，截止2025年9月30日，我武生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股556.20万股，相比上期增加145.24万股。嘉实互融精选股票A（006603）位居第六大流通 股东，持股471.18万股，为新进股东。鹏华医药科技股票A（001230）位居第八大流通股东，持股 429.86万股，为新进股东。招商国证生物医药指数A（161726）位居第十大流通股东，持股390.68万 股，相比上期减少78.33万股。 1月12日，我武生物盘中下跌2.05%，截至13:14，报30.56元/股，成交1.65亿元，换手率1 ...

资料显示，北京九强生物技术股份有限公司位于北京市海淀区花园东路15号旷怡大厦5层，成立日期 2001年3月29日，上市日期2014年10月30日，公司主营业务涉及一家以生化诊断、血凝检测、血型检测 和肿瘤病理检测的研发、生产和销售。主营业务收入构成为：体外检测试剂95.09%，体外检测仪器 3.06%，其他业务收入0.96%，检验服务0.53%，仪器租赁收入0.36%。 1月12日，九强生物盘中上涨2.14%，截至10:55，报13.87元/股，成交6155.71万元，换手率1.06%，总市 值81.32亿元。 资金流向方面，主力资金净流出397.61万元，特大单买入135.38万元，占比2.20%，卖出130.62万元，占 比2.12%；大单买入1132.38万元，占比18.40%，卖出1534.75万元，占比24.93%。 九强生物今年以来股价涨6.12%，近5个交易日涨2.74%，近20日涨1.91%，近60日涨6.03%。 机构持仓方面，截止2025年9月30日，九强生物十大流通股东中，华宝中证医疗ETF（512170）位居第 八大流通股东，持股834.46万股，相比上期减少140.85万股。 责任编 ...

1月12日，海尔生物盘中上涨2.01%，截至09:48，报33.52元/股，成交3367.16万元，换手率0.32%，总市 值106.09亿元。 分红方面，海尔生物A股上市后累计派现7.88亿元。近三年，累计派现4.52亿元。 资金流向方面，主力资金净流入254.31万元，大单买入573.43万元，占比17.03%，卖出319.12万元，占 比9.48%。 机构持仓方面，截止2025年9月30日，海尔生物十大流通股东中，香港中央结算有限公司位居第八大流 通股东，持股673.02万股，相比上期增加92.85万股。华宝中证医疗ETF（512170）位居第十大流通股 东，持股545.57万股，相比上期减少77.69万股。 海尔生物今年以来股价涨5.48%，近5个交易日涨3.30%，近20日涨8.80%，近60日涨0.39%。 资料显示，青岛海尔生物医疗股份有限公司位于山东省青岛市高新区丰源路280号海尔生物医疗新兴产 业园，成立日期2005年10月28日，上市日期2019年10月25日，公司主营业务涉及生物医疗低温存储设备 的研发、生产和销售。主营业务收入构成为：医疗器械及相关产品98.81%，安装收入0.74%， ...